Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

BACKGROUND: The standard neoadjuvant treatments in patients with esophageal squamous cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed in China. METHODS: This was an open-label, single-arm, phase 2 trial. Patients with potentially resectable ESCC (cT1b-3, N...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaofeng, Xu, Xiang, Wang, Danping, Liu, Jinyuan, Sun, Jing, Lu, Mingjie, Wang, Rui, Hui, Bingqing, Li, Xiaofei, Zhou, Chenchen, Wang, Min, Qiu, Tianzhu, Cui, Shiyun, Sun, Nana, Li, Yang, Wang, Fufeng, Liu, Cuicui, Shao, Yang, Luo, Jinhua, Gu, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923273/
https://www.ncbi.nlm.nih.gov/pubmed/36759013
http://dx.doi.org/10.1136/jitc-2022-005830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923273/
https://www.ncbi.nlm.nih.gov/pubmed/36759013
http://dx.doi.org/10.1136/jitc-2022-005830

Ejemplares similares